history, page-10

G'day meerkat,

Yes, it has been a long and slow journey.

My take on it is that the Directors made a choice about how to approach this. Their decision was to get full medical and scientific proof and acceptance first, rather than to employ a team of slick salesmen to push the product into the market.

Whether you agree with the approach or not, it seems that all that hard work is now on the brink of bearing fruit. The product is now undeniably the future of latent TB testing and is accepted as such pretty much by everybody, everywhere.

Sales are increasing and the company is now running in profit. It has no debt, no options (other than a handful of employee options) and no other dilutions. The company owns the product outright and has not sold any of the profits to some US "big-pharma" (as so many others have done over the years). The profits from this will flow directly to the bottom line and into the shareholders pockets.

This year and next should really get the runs on the board.